Chat #1: Introduction to rRNA removal: Evolution of new technologies for bacteria & mammalian samples

View Slides

Learn more about QIAseq FastSelect –rRNA HMR Kits

Learn more about QIAseq FastSelect –5S/16S/23S Kits

Want to try this solution for the first time? Request a trial kit to evaluate

More than 85% of RNA within a sample consists of ribosomal RNA (rRNA). When profiling gene expression using Next-Generation Sequencing (NGS), scientists often attempt to remove ribosomal RNA to both increase sensitivity and decrease overall costs at generating transcriptome wide data.  

Various methods have been developed to remove rRNA, however, these methods are often laborious, take many hours, are inconsistent and expensive, work solely on unfragmented RNA, or simply do not remove enough rRNA due to the complexity and diversity of rRNA in the sample. Novel evolution in rRNA removal technology development has recently led to a new method that addresses these previous concerns. This rapid method is capable of removing more than 95% of the rRNA in human and complex bacterial samples, and can be completed in less than 1 hour for bacterial samples and 14 minutes for mammalian samples.  

Join QIAGEN’s RNAseq R&D team for a discussion on how we developed and benchmarked QIAseq FastSelect HMR and QIAseq FastSelect 5S/16S/23S using both high quality and severely fragmented Total RNA samples, followed by Q&A with our experts.

Jonathan Shaffer, Ph.D.

Jonathan M. Shaffer
Dr. Shaffer joined QIAGEN in 2009 and has since worked with various technology development groups, the most recent being miRNA technologies. He received his Ph.D. in biochemistry and molecular genetics from the University of Pittsburgh School of Medicine in 2008 where his research focused on determining the mechanisms that regulate non-receptor tyrosine kinase expression and activity. Dr. Shaffer did his postdoctoral training at SABiosciences Corporation, now part of QIAGEN. Currently, Dr. Shaffer is a Senior Scientist in Product Development at QIAGEN.
Dr. Sam Rulli

Samuel J. Rulli

Samuel Rulli is an R&D Scientist in qPCR applications at QIAGEN and has spent three years in the biotech industry as a qPCR specialist developing, evaluating, and teaching different qPCR technologies and applications. Dr. Rulli received his PhD in 2002 from Tulane University studying the gastric proton pump and did post-doctoral research at Johns Hopkins University and the National Cancer Institute in Frederick, MD. Trained as a molecular biologist, Dr. Rulli has worked on different assay detection technologies for gene expression and nucleic acid analysis.